Validated MDA-MB-468 Xenograft Model:
Subcutaneous And Orthotopic Xenograft Tumor Model

By Altogen Labs, 11200 Menchaca Road, Suite 203, Austin, TX 78748
Phone: (512) 433-6177 | Email: info@altogenlabs.com

Advancing Breast Cancer Therapy Through Xenograft Studies

Breast cancer remains one of the most prevalent and deadly malignancies worldwide, with diverse subtypes that present unique challenges for treatment. While advancements in targeted therapies have improved outcomes for some patients, aggressive forms such as triple-negative breast cancer (TNBC) continue to lack effective treatment options. To better understand breast cancer biology and develop new therapies, researchers rely on xenograft models, where human tumor cells are implanted into immunocompromised mice. These models closely mimic human tumor growth, allowing for the study of tumor progression, metastasis, and drug response in a controlled environment. Patient-derived xenografts (PDXs) retain the genetic and histopathological characteristics of the original tumor, making them particularly valuable for personalized medicine research. PDX models also maintain the tumor microenvironment, including interactions between tumor cells, stroma, and immune components, offering a more clinically relevant approach for evaluating therapies. Cell line-derived xenografts (CDXs), such as those using MDA-MB-468 cells, provide reproducible models for preclinical drug screening. Xenograft studies have been instrumental in evaluating chemotherapy efficacy, testing novel targeted therapies, and identifying mechanisms of drug resistance.

MDA-MB-468 Cell Line

The MDA-MB-468 cell line is a widely used *in vitro* model for studying triple-negative breast cancer (TNBC), a highly aggressive subtype lacking estrogen receptor (ER), progesterone receptor (PR), and HER2 expression. Derived from the pleural effusion of a 51-year-old Black female patient with metastatic breast adenocarcinoma, these epithelial-like cells exhibit rapid proliferation and genetic alterations commonly associated with TNBC, such as PTEN loss and EGFR overexpression. MDA-MB-468 cells are frequently utilized in cancer research to investigate key signaling pathways, including the PI3K/Akt and MAPK pathways, which drive tumor growth and survival. Their inherent resistance to hormone-targeted therapies makes them essential for screening novel chemotherapeutic agents and targeted treatments. Studies using this cell line have provided critical insights into TNBC biology, including mechanisms of drug resistance and potential therapeutic vulnerabilities. As a result, MDA-MB-468 cells continue to serve as a valuable model for preclinical research aimed at identifying effective treatment strategies for TNBC patients.

Altogen Labs Validated MDA-MB-468 Xenograft Model

After collection from flasks, MDA-MB-468 cells are prepared for injection while ensuring a minimum of 98% cell viability, determined by trypan blue exclusion. The cell suspension is adjusted so that each mouse (athymic BALB/C or NOD/SCID, 10-12 weeks old) receives a single subcutaneous (s.c.) injection into the hind leg, containing one million cells. The injection volume consists of 120-150 µL of a Matrigel and MDA-MB-468 suspension. Tumor growth is monitored using digital calipers until the tumors reach an average size of 50-150 mm³, at which point the study begins. Animals are randomly assigned to treatment cohorts, and test compounds are administered according to the client-provided treatment schedule. Tumor measurements and mouse weights are recorded up to three times a week, and upon completion of the study, animals are humanely euthanized. Collected tissues are processed for termination procedures, including snap freezing, histological fixation, or gene expression analysis. Tumor samples are weighed and imaged using digital options.



Figure 1. MDA-MB-468 breast cancer xenografted in immunocompromised mice, mean values +/- SEM (Altogen Labs).

Xenograft animal models are essential for assessing the effectiveness of drugs against specific cancer types. These models involve engrafting tumor cells via subcutaneous or orthotopic injection into immunocompromised mice or rats to simulate human tumor growth. All clinically approved anti-cancer agents have undergone evaluation using conventional preclinical *in vivo* models. The complexity of xenograft studies includes the selection of the appropriate animal model, tumorigenic cell line, injection method, dosing schedule, and analysis of tumor growth rates, along with histology, mRNA, and protein expression levels. Animal handling at Altogen Labs adheres to IACUC regulations and is GLP-compliant. Mice undergo acclimation and are sorted based on body mass, with daily monitoring for tumor development and clinical signs. We offer comprehensive experimental procedures, health reports, and data analysis, including tissue collection, histology, protein or RNA isolation, and gene expression analysis. Our facilities are equipped to accommodate specialized food or water systems for inducible gene expression research.



Figure 2. Tumor weight of MDA-MB-468 cells in control, buffer only mice and reference compound treated mice at end of the study (Altogen Labs).

Pharmacokinetics and Bystander Effects of T-DXd in MDA-MB-468 Tumors

MDA-MB-468 is a well-established triple-negative breast cancer (TNBC) cell line that expresses very low levels of HER2, making it an important model for evaluating the effectiveness of HER2-targeted therapies in tumors with minimal receptor expression. Unlike HER2-positive cell lines, MDA-MB-468 does not significantly accumulate trastuzumab-deruxtecan (T-DXd) payload, demonstrating a limited correlation between HER2 expression and drug exposure. Despite this, tumor growth inhibition was observed at higher T-DXd doses, suggesting alternative mechanisms, such as the bystander effect, may contribute to its cytotoxic activity. Pharmacokinetic and pharmacodynamic analyses reveal that MDA-MB-468 tumors exhibit lower levels of γH2AX and pRAD50, biomarkers of DNA damage response, compared to HER2-expressing tumors, indicating a less pronounced drug effect. Additionally, HER2 receptor quantification studies show that MDA-MB-468 harbors significantly fewer HER2 receptors per cell compared to HER2-positive models like NCI-N87, further explaining its reduced susceptibility to T-DXd. Despite its resistance to HER2-directed antibody-drug conjugates, MDA-MB-468 remains a valuable model for understanding drug distribution, payload release kinetics, and non-receptor-mediated cytotoxic effects. Future research using this model could refine dosing strategies and identify biomarkers predictive of ADC efficacy in HER2-low or negative tumors.

Metabolic Insights into MDA-MB-468: A Model for TNBC Metabolism

MDA-MB-468 is a widely used cell line that serves as a model for studying metabolic adaptations in aggressive breast tumors. Metabolomic analysis of MDA-MB-468 cell culture media reveals distinct metabolic footprints that highlight the tumor's reliance on key nutrients such as glucose and glutamine. The metabolic profiling of TNBC patient serum, however, shows significant differences from MDA-MB-468 culture media, suggesting that *in vitro* models may not fully replicate systemic metabolic changes in patients. In TNBC patient serum, elevated levels of glucose, glutamine, and citrate contrast with decreased levels of lactate, alanine, and tyrosine, indicating altered energy metabolism and amino acid utilization. MDA-MB-468 cells display a high rate of lactate secretion, a hallmark of the Warburg effect, whereas TNBC patients show reduced serum lactate, possibly due to systemic metabolic adaptations. The study underscores the limitations of monolayer cell cultures in mimicking the metabolic complexity of TNBC *in vivo*. These findings emphasize the importance of integrating both *in vitro* and *in vivo* metabolic analyses to better understand TNBC biology and improve therapeutic targeting strategies.

Subcutaneous Implantation of MDA-MB-468 Cells in Cancer Studies

The subcutaneous MDA-MB-468 xenograft model is a system utilized for studying triple-negative breast cancer (TNBC) *in vivo*. This model involves implanting MDA-MB-468 cells, which originate from a metastatic breast adenocarcinoma, into the subcutaneous tissue of immunocompromised mice, typically athymic BALB/C or NOD/SCID strains. The implanted cells grow into tumors that mimic human breast cancer characteristics, making this model highly relevant for evaluating

tumor progression and therapeutic interventions. Tumor size is regularly measured using digital calipers to monitor growth, and treatment effects can be assessed by comparing tumor volumes in drug-treated versus control groups. This model is particularly valuable for screening anti-cancer drugs, testing chemotherapy regimens, and exploring molecular pathways involved in TNBC. It also serves as a platform to evaluate the effectiveness of targeted therapies and to investigate mechanisms of drug resistance. The subcutaneous MDA-MB-468 model provides essential insights into the biological behavior of aggressive breast cancer and aids in the preclinical development of new treatment strategies.

Orthotopic Implantation of MDA-MB-468 Cells in Cancer Research

The orthotopic MDA-MB-468 xenograft model involves the implantation of MDA-MB-468 cells into the mammary fat pad of immunocompromised mice, closely mimicking human breast cancer's natural tumor microenvironment. This model is particularly valuable for studying the tumor's growth, invasion, and metastasis, as it enables the observation of local and distant spread of cancer cells. Tumors develop within the mammary gland, providing more clinically relevant data on tumor behavior compared to subcutaneous models. The model is used to assess various therapeutic interventions, including chemotherapy, targeted therapies, and immunotherapy, allowing for evaluation of drug efficacy in a setting that reflects the complexity of human breast cancer. It is also crucial for studying cancer metastasis, as MDA-MB-468 cells exhibit the ability to spread to distant organs like the lungs and liver. This orthotopic model has contributed significantly to understanding the molecular mechanisms of tumor progression and metastasis in triple-negative breast cancer (TNBC).

Case Study: Enhanced Tumor Targeting with Anti-EGFR Nanobody-Conjugated Quantum-Dot Micelles

A study by Wang Y, *et al.*, published by *ACS Applied Materials & Interfaces* journal, presents a quantum-dot (QD)-based theranostic micelle conjugated with an anti-epidermal growth factor receptor (EGFR) nanobody (Nb) for targeted triple-negative breast cancer (TNBC) therapy. The micelles, engineered with indium phosphate/zinc sulfide (InP/ZnS) QDs, enable both imaging and drug delivery. MDA-MB-468 cells, a TNBC cell line with high EGFR expression, played a central role in evaluating the micelles' efficacy. The anti-EGFR nanobody, 7D12, significantly enhanced micelle uptake and cytotoxicity in MDA-MB-468 cells compared to non-targeted micelles. Encapsulation of the anticancer drug aminoflavone (AF) within Nb-conjugated micelles led to enhanced tumor accumulation and superior therapeutic efficacy in an orthotopic xenograft mouse model. Notably, targeted micelles demonstrated a 67-fold increase in cellular uptake in MDA-MB-468 cells and induced effective tumor regression, whereas non-targeted micelles had reduced efficacy. Importantly, treatment with the Nb-conjugated micelles showed no observable systemic toxicity, as indicated by stable body weight and normal histology of major organs. These findings highlight the potential of Nb-conjugated QD-based micelles as a promising platform for EGFR-overexpressing TNBC therapy.

Additional Case Study: YC-1 Induces EZH2 Degradation and Inhibits Tumor Growth in MDA-MB-468 Cells

Another study conducted by Chang LC, *et al.*, published by *British Journal of Pharmacology*, investigates the anticancer potential of YC-1 in triple-negative breast cancer (TNBC) with a focus on its effects in MDA-MB-468 cells, a TNBC cell line characterized by high aggressiveness and EGFR overexpression. The findings reveal that YC-1 effectively suppresses MDA-MB-468 cell proliferation and reduces tumor growth in an MDA-MB-468 xenograft mouse model. Mechanistically, YC-1 downregulates the expression of Enhancer of Zeste Homolog 2 (EZH2), a key epigenetic regulator associated with tumor progression. YC-1 induces EZH2 degradation through a proteasome-dependent mechanism, enhancing its ubiquitination via activation of the E3 ubiquitin ligase c-Cbl. The suppression of EZH2 is mediated through the PKA and Src–Raf–ERK signaling pathways, which play a critical role in the regulation of EZH2 stability. Depletion of c-Cbl prevents YC-1-induced EZH2 degradation and apoptosis, underscoring the importance of c-Cbl in this regulatory cascade. Furthermore, YC-1 treatment results in the downregulation of other polycomb repressive complex (PRC) components, including SUZ12 and Bmi1, reinforcing its role in epigenetic reprogramming. Collectively, these findings suggest that YC-1 exerts potent antitumor effects in MDA-MB-468 cells by targeting EZH2 for degradation, highlighting its potential as a therapeutic agent for TNBC.



Figure 3. MDA-MB-468 tumor growth was suppressed when treated with the reference compound (80 mg/kg).

Oncogenic Signaling and Therapeutic Targets in MDA-MB-468 Breast Cancer Cells

MDA-MB-468 is a triple-negative breast cancer (TNBC) cell line characterized by high expression of the epidermal growth factor receptor (EGFR) and aggressive tumorigenic behavior. It harbors mutations in the PTEN gene, leading to dysregulation of the PI3K/AKT signaling pathway, which promotes cell survival and resistance to apoptosis. The PEA-15 phosphoprotein plays a critical role in MDA-MB-468 tumorigenesis by regulating ERK signaling; its overexpression sequesters phosphorylated ERK in the cytoplasm, reducing nuclear transcriptional activity and leading to growth inhibition. Additionally, c-Cbl, an E3 ubiquitin ligase, modulates EGFR degradation, but in MDA-MB-468 cells, its function is impaired, contributing to persistent EGFR signaling and uncontrolled proliferation. This cell line also exhibits dysregulated EZH2, a histone methyltransferase that drives epigenetic changes favoring tumor progression. Experimental therapies targeting these oncogenic drivers, such as enhancing c-Cbl-mediated degradation of EGFR or promoting PEA-15 overexpression, have shown promising tumor-suppressive effects in preclinical models.

Patient-Derived Tumor Organoids for Drug Testing and Screening

Organoids maintain essential characteristics of the original tumor, preserving both genetic and phenotypic diversity. Unlike traditional 2D cell cultures, organoids replicate complex tissue structures and can be expanded efficiently from primary patient samples, making them useful for personalized cancer research and drug testing. While xenograft and allograft models offer insights into tumor-stroma and immune interactions, organoids provide a quicker, more scalable platform for assessing therapeutic responses. Recent breakthroughs in organoid technology have resulted in the development of patient-derived tumor organoid (PDTO) biobanks, which act as living resources to study cancer progression and drug resistance. These models are particularly valuable for high-throughput drug screening, helping researchers pinpoint potential treatments that are tailored to specific tumor characteristics.

Immuno-oncology Xenograft Models

Altogen Labs is a leading preclinical research organization focused on the evaluation of novel pharmacological and biological therapies, with expertise in anticancer treatments, medical compounds, vaccines, cosmetics, and natural products. The company's team of expert scientists utilizes advanced technologies to drive oncology research and accelerate drug development. Altogen Labs offers specialized immuno-oncology services, using humanized and immunodeficient rodent models engrafted with peripheral blood mononuclear cells (PBMC), CD34+ hematopoietic stem cells, and induced pluripotent stem cells (iPSC) to study immune responses, drug efficacy, and toxicity. One of the company's key strengths is its extensive collection of over 100 in-house validated xenograft models, including CDX, patient-derived xenografts (PDX), in vitro patient-derived cell cultures (PDC), and patient-derived organoids (PDOrg), all providing clinically relevant platforms to predict drug efficacy. Additionally, Altogen Labs conducts thorough toxicity studies, assessing acute, sub-chronic, and chronic toxic effects to ensure the safety and long-term tolerability of compounds.



Figure 4. Advanced immune-oncology services available at Altogen Labs (Altogen Labs).

Altogen Labs offers a comprehensive suite of laboratory services with over 30 Cell Line Derived Xenograft (CDX) models and more than 20 Patient-Derived Xenograft (PDX) models, supporting a range of cancer research applications. Researchers exploring the role of specific proteins or gene products in tumor growth regulation can utilize Altogen's services, including the development of genetically engineered cell lines for protein overexpression, such as tumor suppressors or oncogenes, and RNAi-based cell lines with long-term gene silencing. Additionally, Altogen Labs provides quantitative gene expression analysis using RT-PCR for mRNA and employs the WES system (ProteinSimple) for protein expression analysis, ensuring precise results in the evaluation of molecular targets and treatment outcomes.

For the MDA-MB-468 xenograft model, Altogen Labs offers several services, including tumor growth delay (TGD) and tumor growth inhibition (TGI) studies. The laboratory accommodates various dosing regimens, including different frequencies, durations, and routes of administration such as intravenous, intratracheal, subcutaneous, intratumoral, intraperitoneal, oral gavage, and more, utilizing advanced micro-injection techniques and pump-controlled IV injections. Alternative cell engraftment options are available, including orthotopic transplantation, tail vein injection, and mammary fat pad injection, enabling metastasis studies. Additional services include blood chemistry analysis, toxicity and survival monitoring, gross necropsies, histopathology, and imaging studies such as fluorescence-based whole-body imaging. A positive control group can be included using cisplatin to evaluate treatment efficacy.



Figure 5. Available *in vivo* xenograft services at Altogen Labs for MDA-MB-468 (Altogen Labs.)

References:

Bartholomeusz C, Gonzalez-Angulo AM, Kazansky A, Krishnamurthy S, Liu P, Yuan LX, Yamasaki F, Liu S, Hayashi N, Zhang D, Esteva FJ, Hortobagyi GN, Ueno NT. PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinase. *Clin Cancer Res*. 2010 Mar 15;16(6):1802-11. doi: 10.1158/1078-0432.CCR-09-1456. Epub 2010 Mar 9. PMID: 20215547.

Chang LC, Lin HY, Tsai MT, Chou RH, Lee FY, Teng CM, Hsieh MT, Hung HY, Huang LJ, Yu YL, Kuo SC. YC-1 inhibits proliferation of breast cancer cells by down-regulating EZH2 expression via activation of c-Cbl and ERK. *Br J Pharmacol.* 2014 Sep;171(17):4010-25. doi: 10.1111/bph.12708. Epub 2014 Jul 25. PMID: 24697523; PMCID: PMC4243975.

MDA-MB-468 Xenograft. https://altogenlabs.com/xenograft-models/breast-cancer-xenograft/mda-mb-468-xenograft-model/

Vasalou C, Proia TA, Kazlauskas L, Przybyla A, Sung M, Mamidi S, Maratea K, Griffin M, Sargeant R, Urosevic J, Rosenbaum AI, Yuan J, Aluri KC, Ramsden D, Hariparsad N, Jones RDO, Mettetal JT. Quantitative evaluation of trastuzumab deruxtecan pharmacokinetics and pharmacodynamics in mouse models of varying degrees of HER2 expression. *CPT Pharmacometrics Syst Pharmacol.* 2024 Jun;13(6):994-1005. doi: 10.1002/psp4.13133. Epub 2024 Mar 26. PMID: 38532525; PMCID: PMC11179703.

Wang Y, Wang Y, Chen G, Li Y, Xu W, Gong S. Quantum-Dot-Based Theranostic Micelles Conjugated with an Anti-EGFR Nanobody for Triple-Negative Breast Cancer Therapy. *ACS Appl Mater Interfaces.* 2017 Sep 13;9(36):30297-30305. doi: 10.1021/acsami.7b05654. Epub 2017 Aug 28. PMID: 28845963; PMCID: PMC5918284.

Wojtowicz W, Wróbel A, Pyziak K, Tarkowski R, Balcerzak A, Bębenek M, Młynarz P. Evaluation of MDA-MB-468 Cell Culture Media Analysis in Predicting Triple-Negative Breast Cancer Patient Sera Metabolic Profiles. *Metabolites*. 2020 Apr 27;10(5):173. doi: 10.3390/metabo10050173. PMID: 32349447; PMCID: PMC7281562.

Keywords: MDA-MB-468, breast cancer, xenograft, breasts, *in vivo*, cancer, preclinical, research, *in vivo* pharmacology, PDX, CDX, organoids, orthotopic